Setayesh Yazdani

Setayesh Yazdani

Auto-generated profile, based on publicly available information

Setayesh Yazdani

Structural Genomics Consortium, University of Toronto, MaRS South Tower, Suite 700, 101 College Street, Toronto, ON, M5G 1L7, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JNJoseph A. Newman
Joseph A. Newman
ADAlice Douangamath
Alice Douangamath
SYSetayesh Yadzani
Setayesh Yadzani
YYYuliana Yosaatmadja
Yuliana Yosaatmadja
AAAnthony Aimon
Anthony Aimon
OGOpher Gileadi
Opher Gileadi
There is currently a lack of effective drugs to treat people infected with SARS-CoV-2, the cause of the global COVID-19 pandemic. The SARS-CoV-2 Non-structural protein 13 (NSP13) has been identified as a target for anti-virals due to its high sequence conservation and essential role in viral replication. Structural analysis reveals two “druggable” pockets on NSP13 that are among the most conserved sites in the entire SARS-CoV-2 proteome. Here we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and a non-hydrolysable ATP analog. Comparisons of these structures reveal details of conformational changes that provide insights into the helicase mechanism and possible modes of inhibition. To identify starting points for drug development we have performed a crystallographic fragment screen against NSP13. The screen reveals 65 fragment hits across 52 datasets opening the way to structure guided development of novel antiviral agents.

1 March 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
JWJiayan Wang
Jiayan Wang
SYSetayesh Yazdani
Setayesh Yazdani
AHAna Han
Ana Han
MSMatthieu Schapira
Matthieu Schapira

15 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JNJoseph A Newman
Joseph A Newman
ADAlice Douangamath
Alice Douangamath
SYSetayesh Yazdani
Setayesh Yazdani
YYYuliana Yosaatmadja
Yuliana Yosaatmadja
AAAnthony Aimon
Anthony Aimon
OGOpher Gileadi
Opher Gileadi
The global COVID-19 pandemic is caused by the SARS-CoV-2 virus and has infected over 100 million and caused over 2 million fatalities worldwide at the point of writing. There is currently a lack of effective drugs to treat people infected with SARS-CoV-2. The SARS-CoV-2 Non-structural protein 13 (NSP13) is a superfamily1B helicase that has been identified as a possible target for anti-viral drugs due to its high sequence conservation and essential role in viral replication. In this study we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and the non-hydrolysable ATP analogue (AMP-PNP). Comparisons of these structures reveal details of global and local conformational changes that are induced by nucleotide binding and hydrolysis and provide insights into the helicase mechanism and possible modes of inhibition. Structural analysis reveals two pockets on NSP13 that are classified as “druggable” and include one of the most conserved sites in the entire SARS-CoV-2 proteome. To identify possible starting points for anti-viral drug development we have performed a crystallographic fragment screen against SARS-CoV-2 NSP13 helicase. The fragment screen reveals 65 fragment hits across 52 datasets, with hot spots in pockets predicted to be of functional importance, including the druggable nucleotide and nucleic acid binding sites, opening the way to structure guided development of novel antiviral agents.

7 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJiayan Wang
Jiayan Wang
SYSetayesh Yazdani
Setayesh Yazdani
AHAna Han
Ana Han
MSMatthieu Schapira
Matthieu Schapira
Almost twenty years after the human genome was sequenced, the wealth of data produced by the international human genome project has not translated into a significantly improved drug discovery enterprise. This is in part because small molecule modulators that could be used to explore the cellular function of their target proteins and to discover new therapeutic opportunities are only available for a limited portion of the human proteome. International efforts are underway to develop such chemical tools for a few, specific protein families, and a “Target 2035” call to enable, expand and federate these efforts towards a comprehensive chemical coverage of the druggable genome was recently announced. But what is the druggable genome? Here, we systematically review structures of human proteins bound to drug-like ligands available from the protein databank (PDB) and use ligand desolvation upon binding as a druggability metric to draw a landscape of the human druggable genome. We show that the vast majority of druggable protein families, including some highly populated and deeply associated with cancer according to genomic screens, are almost orphan of small molecule ligands, and propose a list of 46 druggable domains representing 3440 human proteins that could be the focus of large chemical probe discovery efforts.